Golden, CO, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Ignite Proteomics LLC, a subsidiary of IMAC Holdings, Inc. (BACK), today announced the completed transfer of Proprietary Laboratory Analyses (PLA) code ...
Explore how proteomics in biomarker discovery accelerates diagnostic assay development and improves clinical validation.
Proteomics has expanded into pulmonary medicine, and can be predicted to develop further for a number of reasons; for example, the potential for obtaining new information, particularly regarding ...
MicroRNAs (miRNAs) are small noncoding RNAs, approximately 22 nucleotides in length, found in diverse organisms. They have emerged in recent years as key regulators of a broad spectrum of cellular ...
This featured session will highlight how multi-omic approaches powered by Seer’s Proteograph Product Suite are transforming translational genomics and clinical research. Brendan Keating, PhD, ...
Association of thymidylate synthase (TS) expression with response to S-1 plus carboplatin (CBDCA) in non-small cell lung cancer (NSCLC) patients (pts). Background: The analysis of clinical breast ...
Ignite Proteomics LLC, a subsidiary of IMAC Holdings, Inc., has successfully transferred the Proprietary Laboratory Analyses (PLA) code 0249U from Theralink Technologies, allowing recognition and ...
Explore how proteomics enhances infectious disease detection, pathogen identification, and host response profiling in ...
Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that the company will be participating in the upcoming TD Cowen 46th Annual Health ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results